Advanced breast cancers that are hormone-receptor-positive are commonly treated with hormonal therapy medicines such as Arimidex (chemical name: anastrazole). Advanced HER2-positive breast cancers are commonly treated with Herceptin (chemical name: trastuzumab).
A study looked at using both Arimidex and Herceptin at the same time in women whose advanced breast cancer was hormone-receptor-positive AND HER2-positive.
The period of time before the cancer progressed was twice as long for the women who received both medicines compared to women who received only Arimidex. In women who received both drugs at the same time, the advanced cancer didn't progress for an additional 2 1/2 months. While this is a modest improvement, the results of this study add to our understanding of and hope for better treatments for advanced breast cancer.